This discrepancy in the findings may be attributed to the fact that the MARS-5 scale assesses independent adjustment of medicine dose as non-adherence to therapy, which may be more common among patients with Type 1 diabetes who frequently monitor their blood sugar levels and independently adjust their insulin doses accordingly. The gene discussed is INS; the disease is type 1 diabetes mellitus.